Cas:4896-76-8 (N,N,O-2H3)Glycine manufacturer & supplier

We serve Chemical Name:(N,N,O-2H3)Glycine CAS:4896-76-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(N,N,O-2H3)Glycine

Chemical Name:(N,N,O-2H3)Glycine
CAS.NO:4896-76-8
Synonyms:N,N,O-trideuterio-glycine;N,N,1-Trideutero-glycin;Glycine-N,N,1-d;glycine-N,N,O-d3;N,N,O-Trideuterio-glycin;N,N,O-d3-glycine;(N,N,O-H)Glycine;MFCD00074933
Molecular Formula:C2H2D3NO2
Molecular Weight:78.085
HS Code:

Physical and Chemical Properties:
Melting point:240ºC (dec.)(lit.)
Boiling point:240.9±23.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.461
PSA:63.32000
Exact Mass:78.050858
LogP:-1.03

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like N,N,O-trideuterio-glycine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00074933 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Glycine-N,N,1-d Use and application,(N,N,O-H)Glycine technical grade,usp/ep/jp grade.


Related News: At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. (N,N,O-2H3)Glycine manufacturer Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings. (N,N,O-2H3)Glycine supplier At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. (N,N,O-2H3)Glycine vendor Travel alerts: As the Wuhan coronavirus spreads around China, infecting more people, a number of countries have raised their travel advisory warnings. (N,N,O-2H3)Glycine factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.